In the summer of 2019, clinicians in several U.S. states reported clusters of severe lung injury in adolescents and adults who had recently used e-cigarette or vaping products. Many had cough, chest pain, shortness of breath, fever, nausea, vomiting, or abdominal pain. Imaging showed bilateral lung abnormalities, but infectious testing often failed to explain the illness.
The syndrome became known as e-cigarette or vaping product use-associated lung injury, EVALI, and by February 2020, the national investigation had recorded more than 2,800 hospitalized cases or deaths and 68 confirmed deaths. The eventual conclusion was careful: vitamin E acetate was strongly linked to the outbreak, especially in THC-containing products, while other chemicals could not be excluded in every case.
How a syndrome is recognized#
An outbreak can begin before anyone knows the agent. Clinicians noticed an unusual combination: young or middle-aged people with severe hypoxemic lung injury, recent vaping, diffuse imaging changes, and no clear infection. State health departments compared reports and alerted CDC.
The case definition required recent e-cigarette or vaping product use, lung opacities, and absence of a more likely diagnosis. Confirmed and probable categories differed in how fully infection was excluded. A surveillance definition helps count cases consistently; it is not a bedside diagnostic test.
This distinction prevents circular reasoning. Vaping history alone did not prove EVALI. The clinical team still had to test for influenza, bacterial pneumonia, COVID-19 later in the pandemic, pulmonary embolism, heart failure, diffuse alveolar hemorrhage, and other causes.
The first descriptive evidence#
The Illinois and Wisconsin case series described 53 patients, most of whom were young and previously healthy. Respiratory, gastrointestinal, and constitutional symptoms were common. Many required intensive care, and one-third needed mechanical ventilation.
Most reported use of THC-containing products, though some used nicotine products and many used both. Product names and sources varied. Descriptive case series cannot estimate population risk because there is no denominator, but they reveal patterns and generate hypotheses; clinicians also documented different pathological injury patterns rather than one pathognomonic lesion. That heterogeneity suggested a toxic inhalation syndrome could have more than one pathway or additive.
Why product history was difficult#
Vaping devices can contain nicotine, THC, cannabidiol, flavorings, solvents, diluents, contaminants, pesticides, metals, or thermal degradation products. Users may switch cartridges, share devices, mix substances, or not know ingredients.
Informal-market THC cartridges were illegal in many jurisdictions, giving patients reason to withhold details. Adolescents might avoid disclosure in front of family. Stigma and fear of law enforcement threatened data quality. Investigators needed confidential, nonjudgmental interviews with specific questions about device, brand, substance, source, frequency, last use, and whether cartridges were modified. Honest clinical disclosure was essential for diagnosis and public health, not punishment.
The THC and informal-source signal#
As reports accumulated, most cases involved THC-containing products. A national MMWR update reported that among hospitalized patients with substance-use information, 82 percent reported THC-containing product use. Many obtained products from informal sources such as friends, family, or dealers.
This association narrowed the search but did not establish which ingredient was harmful. THC itself, a diluent, a contaminant, a pesticide, or heating chemistry could be responsible. Some patients reported only nicotine products, though misclassification, incomplete reporting, and multiple causes remained possible, so the correct move was to go hard at the THC supply chains and keep the other hypotheses open at the same time.
Product testing identified vitamin E acetate#
State and federal laboratories tested cartridges and liquids. Vitamin E acetate appeared frequently in THC-containing samples linked to cases; it had been used as a thickening or diluting agent that could mimic the appearance of concentrated cannabis oil.
Product testing has selection problems. Not every patient retained the exact cartridge used before illness. Submitted products may not represent all use. A positive cartridge cannot prove that its contents reached the injured lung, and a negative cartridge may be the wrong one, though the repeated finding across states provided consistency and a specific candidate. Investigators could then look for the compound in biological specimens.
Lung-fluid evidence strengthened the link#
Bronchoalveolar lavage samples fluid from deep in the lung during bronchoscopy. CDC developed isotope-dilution mass-spectrometry methods to test for vitamin E acetate and other candidates.
In a New England Journal of Medicine analysis, vitamin E acetate was detected in lavage fluid from 48 of 51 EVALI patients across 16 states. It was detected in none of 99 healthy comparison participants, including people who did and did not use e-cigarettes.
THC or nicotine metabolites were also found in patterns consistent with reported use, and finding the suspected diluent at the site of injury substantially strengthened biological coherence beyond self-report or cartridge testing.
The result was not perfect. Three cases lacked detectable vitamin E acetate. Timing, clearance, assay limits, sample differences, misclassification, or another cause could explain them. Strong causation evidence does not require every heterogeneous case to share one agent.
Why vitamin E acetate can harm lungs#
Vitamin E acetate is used in some foods, supplements, and topical products. Route matters. The thin gas-exchange surface deep in your lung is not the digestive tract, and it is not skin. Heating can alter a compound, and aerosol particles deliver it to distal airspaces.
Proposed mechanisms include disruption of pulmonary surfactant, lipid accumulation and inflammation, oxidative injury, and toxic thermal products; laboratory and animal studies provided plausibility, although models cannot reproduce every human product and puff pattern. The episode is a general safety lesson: “food grade” does not mean inhalation grade. Toxicology depends on dose, route, temperature, particle size, co-ingredients, and host susceptibility.
The epidemic curve added temporal evidence#
Emergency visits rose sharply in 2019 and then declined. The decline followed public warnings, removal of vitamin E acetate from some products, changes in consumer behavior, and law-enforcement actions affecting illicit supply.
A falling curve after removal of a suspected agent supports causation, but several interventions happened together. Seasonal respiratory illness, reporting changes, and reduced use could also influence counts. The decline is one strand, not a controlled experiment. The CDC archived investigation summarizes the conclusion: vitamin E acetate was strongly linked, while evidence was insufficient to rule out contributions from other chemicals in THC or non-THC products.
Causation came from triangulation#
The investigation assembled several lines. Temporality was present because product use preceded illness. Strength and consistency appeared in the THC and vitamin E patterns across jurisdictions. Specific biological evidence came from lung fluid. Product testing connected the supply. Toxicology supported plausibility. The decline after intervention supported coherence.
Each line had a weakness. Self-report could be incomplete. Product sampling was selective. Bronchoscopy was performed in a subset. Animal models differ from humans. Multiple public-health changes coincided. Triangulation asks whether biases would have to align implausibly across methods to create the same false conclusion. Convergence made the causal judgment stronger than any P value from one study.
Why “the cause” remained plural in some cases#
EVALI was a surveillance umbrella over several pathological patterns and products. Vitamin E acetate explained much of the outbreak but did not have to explain every patient. Some individuals may have had other toxicants, thermal injury, contaminants, or misclassified disease.
Public-health communication needed two messages at once: act on the major preventable cause and preserve uncertainty. Waiting for proof of one universal mechanism would prolong harm. Claiming exclusivity would stop investigation too early, and this is similar to foodborne outbreaks with one dominant contaminated product and a background of unrelated illnesses that meet an initial symptom definition.
Clinical evaluation#
Symptoms can develop over days or weeks and include cough, chest pain, shortness of breath, fever, chills, fatigue, nausea, vomiting, diarrhea, and abdominal pain. Oxygen saturation and respiratory rate help identify severity. Chest radiography or CT may show bilateral infiltrates.
Evaluation requires a complete product history and tests for infectious and alternative causes; corticosteroids were often used in severe cases, but evidence came mainly from observational experience, and steroids can worsen unrecognized infection. Treatment decisions need specialist and inpatient judgment when illness is substantial.
Some patients worsened rapidly or relapsed after discharge. Follow-up, oxygen reassessment, and avoiding resumed vaping were important. A static article cannot serve as an acute-care protocol.
Vaping risks did not end with the outbreak#
The fall in EVALI cases did not prove vaping became safe. Nicotine addiction, poisoning, burns from devices, respiratory symptoms, cardiovascular effects, youth brain development, and long-term uncertainty remain. THC vaping can impair cognition and carry product-specific risks even without vitamin E acetate.
The National Academies report reviewed evidence on e-cigarette health consequences before EVALI. It found both evidence of harm and uncertainty about long-term outcomes, and for an adult who smokes combustible cigarettes, completely switching to a regulated nicotine product may reduce some toxicant burden, but dual use and youth initiation have different benefit-harm profiles. Do not take up vaping as a health practice. If you are trying to stop nicotine, evidence-based counseling and approved cessation medicines are available with professional guidance.
Public-health surveillance lessons#
Clinician reporting made the cluster visible. Standard case definitions enabled aggregation. Cross-agency laboratory capacity connected products to patients. Rapid communication changed behavior before every mechanism was settled.
Supply-chain data were weak because products were informal and ingredients changed rapidly. Future regulation benefits from ingredient disclosure, manufacturing standards, batch traceability, adverse-event reporting, and authority to test products quickly.
Surveillance must also protect patients. Fear of legal consequences can suppress product histories and delay care. Separating health investigation from punishment improves both ethics and data.
A reusable causation checklist#
When a new health cluster appears, define cases without assuming the cause. Describe person, place, and time. Compare products or behaviors. Obtain representative product and biological specimens. Test competing hypotheses. Seek dose, route, and mechanism. Observe what happens after removal. Continue looking for outliers.
Communicate the level of confidence and the action threshold separately. Public health often must act when evidence is strong enough to prevent harm, before every uncertainty is resolved.
When urgent care is needed#
If you have been vaping and you develop shortness of breath, chest pain, blue lips, low oxygen, confusion, fainting, a severe cough, repeated vomiting, dehydration, or rapid worsening, get evaluated promptly. Tell them everything you used, including THC, nicotine, where it came from, and any modifications; bringing the device or product in may help clinical or public-health assessment, but only when that is safe and someone has asked for it.
References#
- CDC national EVALI investigation
- Vitamin E acetate in lung fluid
- CDC national patient and product update
- Illinois and Wisconsin case series
- CDC lung-fluid laboratory report
- National Academies e-cigarette report
Questions and answers
What was EVALI?
It was an acute or subacute lung-injury syndrome associated with recent e-cigarette or vaping product use, abnormal lung imaging, and no better diagnosis, recognized as a national outbreak in 2019.
Was vitamin E acetate proven to be the only cause?
It was strongly linked to the outbreak and found in most tested case lung-fluid samples, but CDC did not rule out other chemicals or more than one mechanism in some cases.
Were only nicotine products involved?
No. Most outbreak patients with available information reported THC-containing products, often from informal sources, although some reported nicotine products or incomplete product histories.
Is vitamin E safe to inhale because it is used in foods or skin products?
No. Safety depends on route and processing. Heating and inhaling an oily compound into distal lung tissue is not equivalent to eating or applying it to skin.
What symptoms need urgent assessment after vaping?
Shortness of breath, chest pain, low oxygen, severe cough, confusion, repeated vomiting, or rapid worsening require prompt medical evaluation and honest disclosure of all products used.